Aclaris Q4 net loss $27.6M; revenue $7.8M on licensing; cash $229.8M through 2025

Aclaris Therapeutics, Inc.

2022-FY EPS reported -$1.33 revenue$29,752,000

Q4 2022 net loss $27.6M vs $22.8M in Q4 2021; full-year net loss $86.9M vs $90.9M.
Q4 total revenue $7.8M (incl. $6.7M licensing, $5M from Pediatrix) vs $1.5M prior year.
Cash, equivalents and marketable securities $229.8M; expected to fund operations through end of 2025.
Phase 2a zunsemetinib HS topline data expected March 2023; Phase 2b RA data H2 2023.
Phase 2b ATI-1777 atopic dermatitis topline data mid-2023; Phase 1 MAD ATI-2138 data H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.